Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline Cloos

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study GroupKim Klein, Gertjan Kaspers, Christine J Harrison, et al.
British Journal of Haematology|April 21, 2018
An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemiaGertjan J L Kaspers, Denise Niewerth, Bram A J Wilhelm, et al.
Haematologica|July 28, 2011
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaBrian V Balgobind, Iris H I M Hollink, Susan T C J M Arentsen-Peters, et al.
PLOS Digital Health|January 9, 2025
A data management system for precision medicineJohn J L Jacobs, Inés Beekers, Inge Verkouter, et al.
Plos One|January 16, 2013
Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cellsMahban Irandoust, Julian Alvarez Zarate, Isabelle Hubeek, et al.
Nature Genetics|December 25, 2012
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Zeynep Kalender Atak, Ning Li, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Haematologica|October 26, 2010
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemiaBrian V Balgobind, Marry M Van den Heuvel-Eibrink, Renee X De Menezes, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Leukemia|September 3, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialTim R Mocking, Lukas H Haaksma, Tom Reuvekamp, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study GroupKim Klein, Gertjan Kaspers, Christine J Harrison, et al.
British Journal of Haematology|April 21, 2018
An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemiaGertjan J L Kaspers, Denise Niewerth, Bram A J Wilhelm, et al.
Haematologica|July 28, 2011
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaBrian V Balgobind, Iris H I M Hollink, Susan T C J M Arentsen-Peters, et al.
PLOS Digital Health|January 9, 2025
A data management system for precision medicineJohn J L Jacobs, Inés Beekers, Inge Verkouter, et al.
Plos One|January 16, 2013
Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cellsMahban Irandoust, Julian Alvarez Zarate, Isabelle Hubeek, et al.
Nature Genetics|December 25, 2012
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Zeynep Kalender Atak, Ning Li, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Haematologica|October 26, 2010
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemiaBrian V Balgobind, Marry M Van den Heuvel-Eibrink, Renee X De Menezes, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Leukemia|September 3, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trialTim R Mocking, Lukas H Haaksma, Tom Reuvekamp, et al.
Pageof 18